Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00680719 · ClinicalTrials.gov registry record · Phase 1
Preventing HIV/Aids in Drug Abusing Youth
A Phase 1 study of HIV Infections, sponsored by Oregon Research Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 111
- Enrollment target
- 1
- Study location
NCT00680719: Completed Phase 1 study of HIV Infections, sponsored by Oregon Research Institute.
NCT00680719 is a Phase 1 study of HIV Infections that has completed, run by Oregon Research Institute. The registered enrollment target is 111 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (75% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00680719, a Phase 1 study of HIV Infections, has completed, sponsored by Oregon Research Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 111 participants
- Enrollment target
- 1
- Study location
Study Summary
This project involves two studies focusing on the engagement and treatment of adolescents diagnosed with substance use disorders. Study 1 will evaluate a promising parent-based engagement intervention, Community Reinforcement Training, designed to facilitate the entry of resistant drug-abusing adolescents in treatment. The approach will be compared with an Engagement As Usual intervention condition. Study 2 involves a controlled clinical trial evaluating the efficacy of an HIV/AIDS prevention intervention embedded in family-based drug abuse treatment for reducing HIV/AIDS risk behaviors and substance use. Adolescents who are successfully engaged in treatment through Study 1 will be randomly assigned to receive either family therapy alone or family therapy with the integrated HIV/AIDS prevention intervention. Both studies are being conducted in Portland, Oregon.
Conditions Studied
Interventions
- BEHAVIORAL IBFT /HIV prevention
- BEHAVIORAL IBFT
Study Locations (1)
Oregon
- Oregon Research Institute Center for Family and Adolescent Research - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 111 participants |
| Start Date | 2004-06 |
| Est. Completion | 2013-06 |
| Phase | Phase 1 |
What the finished NCT00680719 record still lists
NCT00680719 is an interventional study that assigns participants to a tested intervention. The registered 111 participants enrollment target is mid-sized for trials with a published cap, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (75% lower).
The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 2 interventions - of which IBFT /HIV prevention is the first listed.
NCT00680719 reports a single indexed study location in Oregon.
Frequently Asked Questions
What is clinical trial NCT00680719 about?
NCT00680719 is a clinical study titled "Preventing HIV/Aids in Drug Abusing Youth". This project involves two studies focusing on the engagement and treatment of adolescents diagnosed with substance use disorders. Study 1 will evaluate a promising parent-based engagement intervention, Community Reinforcement Training, designed to facilitate the entry of resistant drug-abusing adole...
What is the current status of trial NCT00680719?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 111 participants. The study started on 2004-06. Estimated completion is 2013-06.
What conditions does trial NCT00680719 study?
This clinical trial studies the following conditions: HIV Infections.
What interventions are being tested in trial NCT00680719?
The interventions under investigation include: IBFT /HIV prevention (BEHAVIORAL), IBFT (BEHAVIORAL).
Who is sponsoring clinical trial NCT00680719?
This trial is sponsored by Oregon Research Institute, which has 62 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00680719 being conducted?
This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00680719's enrollment target sits among peer trials
111 253rd of 542 higher than 290 of 542 other HIV Infections trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HIV Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
CAR-T Cells for HIV Infection
RECRUITING · Phase 1
-
A Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIV
RECRUITING · Phase 1
-
Clinical Trial to Evaluate the Safety and Immunogenicity of Hiltonol, Poly-ICLC-adjuvanted CD40.HIVRI.Env (VRIPRO) in Adult Participants Who Previously Participated in HVTN 706
RECRUITING · Phase 1
-
Pharmacokinetics, Safety, Tolerability of Dolutegravir/Rilpivirine in Pediatrics
RECRUITING · Phase 1
-
A Study to Investigate Pharmacokinetics, Safety and Tolerability of Long-Acting Cabotegravir Plus Recombinant Human Hyaluronidase PH20 in Healthy Adult Participants
RECRUITING · Phase 1
-
First Time in Human Study of Long Acting VH4524184 Formulations
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03875716 · 111 participants · NA
Study of De_Intensified Postoperative Radiation Therapy for HPV Associated Oropharyngeal Squamous Cell Carcinoma
- NCT04693468 · 111 participants · Phase 1
Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial
- NCT05263050 · 111 participants · Phase 2
Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors
- NCT05600842 · 111 participants
De-escalated Radiation for Human Papillomavirus-Positive Squamous Cell Carcinoma of the Oropharynx
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia